Herein, we identified ICAM1 as an optimal ADC target for cervical cancer and used it to construct two ADCs using the same linker and payload combinations of Tisotumab Vedotin and Trastuzumab Deruxtecan, and comprehensively explored their impacts on TAN elimination and polarization during ADC treatment. This evidence concerns the gene ICAM1 and cervical cancer.